{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:58:01Z","timestamp":1790477881042,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"DOI":"10.7759\/cureus.85343","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:10:57Z","timestamp":1749049857000},"source":"Crossref","is-referenced-by-count":2,"title":["Postmarket Safety Surveillance of FDA-Cleared Prescription Digital Therapeutics Using the Manufacturer and User Facility Device Experience (MAUDE) Database: A Pharmacovigilance Study"],"prefix":"10.7759","author":[{"given":"Shaheen E","family":"Lakhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82793","article-title":"When software becomes medicine: ignoring it may soon be malpractice","volume":"17","author":"Lakhan SE","year":"2025","unstructured":"Lakhan SE. When software becomes medicine: ignoring it may soon be malpractice. Cureus. 2025, 17:10.7759\/cureus.82793","journal-title":"Cureus"},{"key":"ref2","unstructured":"Manufacturer and User Facility Device Experience (MAUDE) Database. (2025). Accessed. May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfmaude\/search.cfm."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081518","article-title":"Late adverse event reporting from medical device manufacturers to the US Food and Drug Administration: cross sectional study","volume":"388","author":"Everhart AO","year":"2025","unstructured":"Everhart AO, Karaca-Mandic P, Redberg RF, Ross JS, Dhruva SS. Late adverse event reporting from medical device manufacturers to the US Food and Drug Administration: cross sectional study. BMJ. 2025, 388:10.1136\/bmj-2024-081518","journal-title":"BMJ"},{"key":"ref4","unstructured":"Device classification under section 513(f)(2)(De Novo). (2017). Accessed. May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?ID=DEN160018."},{"key":"ref5","unstructured":"510(k) Premarket notification. (2018). Accessed. May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K173681."},{"key":"ref6","unstructured":"510(k) Premarket notification. Device name. Somryst. (2020). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K191716."},{"key":"ref7","unstructured":"Device classification under section 513(f)(2)(De Novo). Device name. EndeavorRx. (2020). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?ID=DEN200026."},{"key":"ref8","unstructured":"510(k) Premarket notification. Device name. Mahana Parallel Digital Cognitive Behavioral Therapy (CBT) Mobile Application for Irritable Bowel Syndrome (IBS). (2021). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K211372."},{"key":"ref9","unstructured":"510(k) Premarket notification. Device name. Regulora. (2021). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K211463."},{"key":"ref10","unstructured":"Device classification under section 513(f)(2)(De Novo). Device name. Stanza. (2023). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?ID=DEN220083."},{"key":"ref11","unstructured":"Device classification under section 513(f)(2)(De Novo). Device name. BT-001. (2023). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?ID=DEN220058."},{"key":"ref12","unstructured":"FDA. 510(k) Premarket notification. Device name. Rejoyn. (2024). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K231209."},{"key":"ref13","unstructured":"510(k) Premarket notification. Device name. Daylight. (2024). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K233872."},{"key":"ref14","unstructured":"510(k) Premarket notification. Device name. MamaLift Plus. (2024). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K223515."},{"key":"ref15","unstructured":"510(k) Premarket notification. Device name. Sleepio. (2024). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K233577."},{"key":"ref16","unstructured":"Device classification under section 513(f)(2)(De Novo). Device name. CT-132. (2025). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?ID=DEN240064."},{"key":"ref17","unstructured":"Somryst. Clinician instructions for use. (2024). Accessed. May 14, 2025: https:\/\/noxmedical.com\/wpcontent\/ uploads\/2025\/01\/Somryst-Clinician-Instructions-for-Use-2.0.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2196\/51225","article-title":"The impact of intervention design on user engagement in digital therapeutics research: factorial experiment with a mixed methods study","volume":"8","author":"Lee H","year":"2024","unstructured":"Lee H, Choi EH, Shin JU, et al.. The impact of intervention design on user engagement in digital therapeutics research: factorial experiment with a mixed methods study. JMIR Form Res. 2024, 8:10.2196\/51225","journal-title":"JMIR Form Res"},{"key":"ref19","unstructured":"MAUDE Adverse Event Report. autonomous user rehabilitation agent; computerized behavioral therapy device for psychiatric disorders. (2022). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfmaude\/detail.cfm?mdrfoi__id=14117437."},{"key":"ref20","unstructured":"MAUDE Adverse Event Report. Akiliinteractive Labs, Inc. Endeavorotc; digital therapeutic software for attention deficit hyperactivity disorder. (2023). Accessed: May 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfmaude\/detail.cfm?mdrfoi__id=17799340."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.30","article-title":"Medical device recalls and the FDA approval process","volume":"171","author":"Zuckerman DM","year":"2011","unstructured":"Zuckerman DM, Brown P, Nissen SE. Medical device recalls and the FDA approval process. Arch Intern Med. 2011, 171:1006-11. 10.1001\/archinternmed.2011.30","journal-title":"Arch Intern Med"},{"key":"ref22","unstructured":"Developing a software precertification program. a working model. (2019). Accessed: May 14, 2025: https:\/\/www.fda.gov\/media\/119722\/download."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372791-postmarket-safety-surveillance-of-fda-cleared-prescription-digital-therapeutics-using-the-manufacturer-and-user-facility-device-experience-maude-database-a-pharmacovigilance-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:10:59Z","timestamp":1749049859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372791-postmarket-safety-surveillance-of-fda-cleared-prescription-digital-therapeutics-using-the-manufacturer-and-user-facility-device-experience-maude-database-a-pharmacovigilance-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.85343","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}